MedGenesis strengthens position in CNS

Published: 14-Jan-2010
Research & Development

MedGenesis Therapeutix granted licence to Amgen\'s GDNF protein


MedGenesis Therapeutix, a developer of drugs for patients with central nervous system (CNS) diseases, has been granted an exclusive, worldwide licence to Amgen's glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications. As part of the agreement, Amgen has taken a small equity stake in MedGenesis.

In parallel, MedGenesis has signed an agreement with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, Canada's largest pharmaceutical company, to collaborate on the development of GDNF in Parkinson's disease and potentially other CNS indications.

Biovail, which is also a party to the Amgen licence for CNS indications, has a co-exclusive licence to sell GDNF in the US, Canada, Japan and a number of European countries.

MedGenesis has also granted Biovail a licence to its Convection Enhanced Delivery (CED) platform for use with GDNF in CNS indications.

"We believe that our Convection Enhanced Delivery approach will result in accurate, targeted delivery of GDNF to the regions of the brain affected by Parkinson's disease and holds the promise of providing patients for the first time with a treatment which could potentially modify the disease, rather than just treat the symptoms," said Erich Mohr, chairman and ceo of MedGenesis.

See more

You may also like

Research & Development

Oxford Nanopore gets cash injection

Read more
Biotech company Amgen has announced a £50m (US$66m) equity investment in the UK-based company developing real-time genetic sequencing technology

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  3. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  4. Ryvu to support BioNTech’s clinical trials for cancer in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients
  5. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

Oxford Nanopore gets cash injection

Biotech company Amgen has announced a £50m (US$66m) equity investment in the UK-based company developing real-time genetic sequencing technology
Research & Development

Amgen and Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

Immatics to receive $30 million upfront and potentially more than $1 billion in milestone payments plus royalties
Research & Development

Biocartis and Amgen sign a RAS biomarker testing collaboration in Europe

Biocartis, an innovative molecular diagnostics company, has signed a new collaboration agreement with Amgen, a leading biotechnology company
Research & Development

Teijin Pharma and Amgen to jointly research and develop new therapy for kidney diseases

Teijin Pharma Limited has entered into a collaboration and license agreement with a leading biotechnology company, Amgen, regarding research and development of new therapeutic agents for kidney diseases and disorders
You need to be a subscriber to read this article.
Click here to find out more.
Media

A precision medicine approach to developing cancer vaccines

Modern anticancer medicines represent a significant improvement on one-size-fits-all chemotherapy, reports Dr Sarah Houlton
Regulatory

Hyperparathyroidism - etelcalcetide

Kidney dialysis patients often develop secondary hyperparathyroidism (SHPT), which can cause additional health issues in those with end-stage disease
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Homing in on cancer targets

Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Subscribe now